Duchenne Muscular Dystrophy Market Size was ~USD 1,700 million in 2022 and expected to Grow from (2024-2034), estimates DelveInsight | Sarepta Therapeutics, Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biop

The Duchenne Muscular Dystrophy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.

DelveInsight's "Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Duchenne Muscular Dystrophy, historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Duchenne Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Duchenne Muscular Dystrophy Market Report:
• The Duchenne Muscular Dystrophy market size was valued approximately USD 1,700 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In January 2024, Santhera Pharmaceuticals initiated the availability of AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) patients aged four years and older in Germany. This marks a significant milestone as Santhera Pharmaceuticals transitions into the "commercial stage" of its biopharmaceutical journey through the official launch of this medication in Germany.
• In 2023, the United States reported approximately 17,000 total prevalent cases of Duchenne muscular dystrophy (DMM). The majority of cases were observed in children aged 5-9 years. It is anticipated that these numbers will increase by the year 2034.
• In 2023, the United States had the highest number of prevalent cases of Duchenne muscular dystrophy (DMM) among the 7MM countries, totaling approximately 17,200 cases. This figure is projected to rise at a respectable compound annual growth rate (CAGR).
• In the United States in 2023, there were approximately 13,800 cases of large mutation, around 3,400 cases of small mutation, and roughly 1,700 cases of point mutation. It is anticipated that as prevalence rates rise, these numbers will also increase during the study period from 2024 to 2034.
• In the EU4 countries (Germany, France, Italy, and Spain) along with the United Kingdom, the highest prevalence of Duchenne Muscular Dystrophy (DMD) was observed in the UK, totaling approximately 3,000 cases in 2022. This was followed by Germany and France, whereas Spain had the lowest number of cases recorded in the same year.
• In the present US market, there are several approved products-EMFLAZA (deflazacort), VYONDYS 53 (golodirsen), EXONDYS 51 (eteplirsen), AMONDYS 45 (casimersen), and VILTEPSO (viltolarsen)-available for individuals with Duchenne Muscular Dystrophy (DMD). Within the EU4 countries and the UK, steroid therapies dominate the current market, accompanied by an approved medication designed for DMD patients with the nonsense mutation, TRANSLARNA (ataluren). However, in Japan, the sole approved treatment available is VILTEPSO (viltolarsen).
• Key Duchenne Muscular Dystrophy Companies: Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others
• Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others
The Duchenne Muscular Dystrophy epidemiology based on gender analyzed that Duchenne Muscular Dystrophy rarely affects females
• In 2023, the age group with the highest number of cases was 5-9, totaling approximately 5,700 cases, followed by the 10-14 age group with around 5,000 cases. Duchenne muscular dystrophy (DMD) is uncommon in individuals above the age of 30.
• The Duchenne Muscular Dystrophy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.

Request for Free Sample Report for Latest Duchenne Muscular Dystrophy Statistics: https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Duchenne Muscular Dystrophy Overview
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It primarily affects males, typically becoming apparent in early childhood, around ages 3 to 5. Duchenne Muscular Dystrophy is caused by mutations in the dystrophin gene, which leads to the absence or dysfunction of the dystrophin protein crucial for maintaining muscle integrity. Symptoms include muscle weakness, difficulty walking, frequent falls, and eventually, difficulty with breathing and heart function.
Duchenne Muscular Dystrophy Diagnosis often involves genetic testing and muscle biopsy. While there is no cure for Duchenne Muscular Dystrophy, various interventions aim to manage symptoms, slow disease progression, and improve quality of life. This may include physical therapy, orthopedic interventions like braces or surgery, respiratory support, and medications like corticosteroids. Emerging therapies such as gene therapy and exon skipping hold promise for future treatments.
Duchenne Muscular Dystrophy has a progressive course, with most individuals losing the ability to walk by their early teens and experiencing life-threatening complications in adulthood. However, advancements in care and management have extended life expectancy and improved outcomes for many individuals with Duchenne Muscular Dystrophy, emphasizing the importance of comprehensive multidisciplinary care and support for patients and their families.

Get a Free sample for the Duchenne Muscular Dystrophy Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Duchenne Muscular Dystrophy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Duchenne Muscular Dystrophy Epidemiology Segmentation:
The Duchenne Muscular Dystrophy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Duchenne Muscular Dystrophy
• Prevalent Cases of Duchenne Muscular Dystrophy by severity
• Gender-specific Prevalence of Duchenne Muscular Dystrophy
• Diagnosed Cases of Episodic and Chronic Duchenne Muscular Dystrophy

Download the report to understand which factors are driving Duchenne Muscular Dystrophy epidemiology trends @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Duchenne Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Duchenne Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Duchenne Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Duchenne Muscular Dystrophy Therapies and Key Companies
• Givinostat (ITF2357): Italfarmaco
• ATL1102: Antisense Therapeutics
• SRP-9001: Sarepta Therapeutics
• Vamorolone: Santhera Pharmaceuticals/ReveraGen Biopharma
• PF06939926: Pfizer
• Pamrevlumab: FibroGen
• CAP-1002: Capricor Therapeutics
• Pamrevlumab: Fibrogen
• Delandistrogene moxeparvovec: Roche/Sarepta Therapeutics
• EDG 5506: Edgewise Therapeutics
• WVE N531: Wave Life Sciences Ltd
• PGN EDO51: PepGen
• UX810: Ultragenyx Pharmaceutical

Request for Sample Report @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Duchenne Muscular Dystrophy Market Strengths
The pipeline of DMD is robust with the advent of several potential products in late-stage of clinical development.
Several new therapies have been approved for the treatment of DMD recently, even Japan has witnessed the launch of VILTEPSO now.

Duchenne Muscular Dystrophy Market Opportunities
Wider commercial opportunity for therapies such as Capricor's CAP-1002 and Antisense's ATL1102, which are specifically focusing on improving upper limb functions in DMD patients and are targeting a much larger patient segment when compared to the Exon-Skipping therapies.

Scope of the Duchenne Muscular Dystrophy Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Duchenne Muscular Dystrophy Companies: Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others
• Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others
• Duchenne Muscular Dystrophy Therapeutic Assessment: Duchenne Muscular Dystrophy current marketed and Duchenne Muscular Dystrophy emerging therapies
• Duchenne Muscular Dystrophy Market Dynamics: Duchenne Muscular Dystrophy market drivers and Duchenne Muscular Dystrophy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Duchenne Muscular Dystrophy Unmet Needs, KOL's views, Analyst's views, Duchenne Muscular Dystrophy Market Access and Reimbursement

To know more about Duchenne Muscular Dystrophy companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Duchenne Muscular Dystrophy Market Report Introduction
2. Executive Summary for Duchenne Muscular Dystrophy
3. SWOT analysis of Duchenne Muscular Dystrophy
4. Duchenne Muscular Dystrophy Patient Share (%) Overview at a Glance
5. Duchenne Muscular Dystrophy Market Overview at a Glance
6. Duchenne Muscular Dystrophy Disease Background and Overview
7. Duchenne Muscular Dystrophy Epidemiology and Patient Population
8. Country-Specific Patient Population of Duchenne Muscular Dystrophy
9. Duchenne Muscular Dystrophy Current Treatment and Medical Practices
10. Duchenne Muscular Dystrophy Unmet Needs
11. Duchenne Muscular Dystrophy Emerging Therapies
12. Duchenne Muscular Dystrophy Market Outlook
13. Country-Wise Duchenne Muscular Dystrophy Market Analysis (2020-2034)
14. Duchenne Muscular Dystrophy Market Access and Reimbursement of Therapies
15. Duchenne Muscular Dystrophy Market Drivers
16. Duchenne Muscular Dystrophy Market Barriers
17. Duchenne Muscular Dystrophy Appendix
18. Duchenne Muscular Dystrophy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Alopecia Aerata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Brain Cancer Market: https://www.delveinsight.com/report-store/brain-cancer-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Biliary Tumor Market: https://www.delveinsight.com/report-store/biliary-tumor-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Reactive Arthritis Market: https://www.delveinsight.com/report-store/reactive-arthritis-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.